Liver Cancer Clinical Trials

• Histological or cytological confirmed advanced colon cancer with liver metastasis.

• Signed written informed consent.

• Have not received anti-tumor treatment.

• According to the investigators assessment, at least one measurable target lesion defined by RECIST v1.1.

• Patients of both sexes, aged ≥18 years and ≤75 years.

• ECOG PS 0-1;

• Expected survival time ≥ 3 months;

• Have adequate organ and bone marrow function, laboratory examination within 7 days prior to enrollment meets the following requirements, as follows:

⁃ 1\) Blood routine: ANC ≥ 1.5 × 10\^9/L, Platelet count ≥ 100 × 10\^9/L, HGB ≥100 g/L (no blood transfusion or erythropoietin dependence within 14 days); 2) Liver function: TBIL ≤1.5 x ULN; ALT/AST ≤ 5 x ULN; ALP ≤5×ULN; 3) Renal function: Cr ≤1.5×ULN, or creatinine clearance ≥50 mL/min: Urine routine results showed urinary protein \< 2+; 4) Coagulation function: INR or PT ≤1.5 x ULN. 9.For female subjects of reproductive age, a urine or serum pregnancy test should be performed and the result is negative 3 days prior to receiving the initial study drug administration.

⁃ 10\. For women of childbearing potential (WOCBP): agreement to refrain from heterosexual intercourse or use contraception.

⁃ 11\. For men: agreement to refrain from heterosexual intercourse or use a condom, and agreement to refrain from donating sperm.